Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients? Alain Antoine MinaBrady Stein Myeloproliferative Neoplasms (B Stein, Section Editor) 30 April 2019 Pages: 137 - 144
Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms Laura F. Mendez LuqueAmanda L. BlackmonAngela G. Fleischman Myeloproliferative Neoplasms (B Stein, Section Editor) 22 May 2019 Pages: 145 - 153
Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment Hany ElmariahAmy E. DeZern Myeloproliferative Neoplasms (B Stein, Section Editor) 15 May 2019 Pages: 154 - 163
Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions Prathibha SurapaneniRobyn M. Scherber Myeloproliferative Neoplasms (B Stein, Section Editor) 15 May 2019 Pages: 164 - 170
Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come? Jennifer E. VaughnVeena ShankaranRoland B. Walter Health Economics (N Khera, Section Editor) 11 May 2019 Pages: 171 - 178
Disparities in Survival and Health Outcomes in Childhood Leukemia Lena E. WinestoneRichard Aplenc Health Economics (N Khera, Section Editor) 09 May 2019 Pages: 179 - 186
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma M. OffidaniM. BoccadoroM. Cavo Multiple Myeloma (P Kapoor, Section Editor) 10 May 2019 Pages: 187 - 196
Targeting BTK in CLL: Beyond Ibrutinib David A. BondJennifer A. Woyach ReviewPaper 27 April 2019 Pages: 197 - 205